Last updated: July 20, 2026
Azurity Pharmaceuticals v. Zydus Pharmaceuticals (USA) 1:23-cv-00833: Litigation Summary, Patent Issues, and Generic-Entry Risk Analysis
Azurity Pharmaceuticals, Inc. v. Zydus Pharmaceuticals (USA) Inc., case number 1:23-cv-00833, is a Hatch-Waxman patent infringement dispute filed in the US District Court (case style shown by the docket caption). The available information in this chat does not include the asserted patents, the Orange Book listing(s) at issue, the Delaware-style “Yea/Nea” infringement allegations, or the specific Paragraph IV certifications and FDA ANDA/approval posture tied to the suit. Without those docket-specific particulars, a complete, accurate litigation summary and patent-by-patent analysis cannot be produced.
What is the case background for Azurity v. Zydus 1:23-cv-00833?
Answer: Not determinable from the information provided.
What product and ANDA are implicated in 1:23-cv-00833?
Answer: Not determinable from the information provided.
When was the complaint filed and when were key scheduling events set?
Answer: Not determinable from the information provided.
Which patents does Azurity assert against Zydus in 1:23-cv-00833?
Answer: Not determinable from the information provided.
Are the asserted patents Orange Book-listed for the reference listed drug?
Answer: Not determinable from the information provided.
Which patent categories are typically asserted in this posture (composition, method-of-use, formulation, manufacturing)?
Answer: Not determinable from the information provided.
What Paragraph IV certifications are challenged in Azurity v. Zydus 1:23-cv-00833?
Answer: Not determinable from the information provided.
What is alleged about “not infringed,” “invalid,” or “unenforceable” grounds?
Answer: Not determinable from the information provided.
What does the court procedural record show for 1:23-cv-00833?
Answer: Not determinable from the information provided.
Any motions to dismiss, transfer, stay, or claim-construction filings?
Answer: Not determinable from the information provided.
Have Markman/claim construction, summary judgment, or trial dates been set?
Answer: Not determinable from the information provided.
How strong is Azurity’s patent position in 1:23-cv-00833?
Answer: Not determinable from the information provided.
How many asserted patents are typically in play and what expiration dates matter for exclusivity?
Answer: Not determinable from the information provided.
Are there known prior PTAB challenges (IPR), reexaminations, or related cases affecting validity?
Answer: Not determinable from the information provided.
What generic entry risks exist for Zydus based on 1:23-cv-00833?
Answer: Not determinable from the information provided.
Could this litigation end in a settlement affecting launch date or design-around claims?
Answer: Not determinable from the information provided.
Does the case include partial invalidity or non-infringement arguments that could preserve later launch?
Answer: Not determinable from the information provided.
How does this case compare with other Azurity vs. generic defendants in Hatch-Waxman litigation?
Answer: Not determinable from the information provided.
What is the likely FDA regulatory posture tied to 1:23-cv-00833?
Answer: Not determinable from the information provided.
Is Zydus’ application stayed under 21 U.S.C. § 355(j)(5)(B)(iii) and for which patents?
Answer: Not determinable from the information provided.
Does the case suggest an at-risk launch scenario if FDA approval is otherwise available?
Answer: Not determinable from the information provided.
Key Takeaways
- The docket citation alone is insufficient to produce a complete litigation summary and patent-by-patent analysis for Azurity Pharmaceuticals, Inc. v. Zydus Pharmaceuticals (USA) Inc., 1:23-cv-00833.
- A correct, actionable summary requires the specific asserted patents and the litigation filings tied to infringement/validity positions, which are not present in the information provided here.
FAQs
- What is the Orange Book status of the drug at issue in Azurity v. Zydus 1:23-cv-00833?
- What patents are subject to the Paragraph IV certifications in this case?
- Has the court issued any claim construction order in 1:23-cv-00833?
- Does the litigation outcome affect Zydus’ potential generic launch date?
- Are there related cases involving the same drug, patents, or parties?
References
No sources cited because the required docket-specific facts (asserted patents, FDA listing, procedural history, and filings) are not included in the information provided.
